Name:	dvax_PotentialMilestonePaymentAmount
Namespace Prefix:	dvax_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research Collaboration and License Agreement Period

+ References

No definition available.

+ Details

Name:	dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Period

+ References

No definition available.

+ Details

Name:	dvax_RevenueRecognitionPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 910

-SubTopic 310

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph c

-Article 5

+ Details

Name:	us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_ProductInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaborative Research, Development, and License Agreements - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended		12 Months Ended				1 Months Ended	3 Months Ended		12 Months Ended		1 Months Ended	12 Months Ended	3 Months Ended								1 Months Ended
	Dec. 31, 2008 Glaxo, Smith, Kline Project	Mar. 31, 2013 Glaxo, Smith, Kline	Mar. 31, 2012 Glaxo, Smith, Kline	Dec. 31, 2011 Glaxo, Smith, Kline	Dec. 31, 2012 Glaxo, Smith, Kline	Dec. 31, 2011 Glaxo, Smith, Kline Expansion	Mar. 31, 2013 Glaxo, Smith, Kline Maximum	Mar. 31, 2013 Glaxo, Smith, Kline Follow-On TLR 7/9 program and other TLR programs Maximum	Mar. 31, 2013 Glaxo, Smith, Kline Annual net sales milestones achieved Maximum	Sep. 30, 2006 Astra Zeneca	Mar. 31, 2013 Astra Zeneca	Mar. 31, 2012 Astra Zeneca	Dec. 31, 2008 Astra Zeneca	Dec. 31, 2012 Astra Zeneca	Oct. 31, 2011 Astra Zeneca Amendment	Dec. 31, 2011 Astra Zeneca Amendment	Mar. 31, 2013 Astra Zeneca Advance the program following completion of Phase 2a Amendment	Dec. 31, 2012 Astra Zeneca Advance the program following completion of Phase 2a Amendment	Mar. 31, 2012 Astra Zeneca Advance the program following completion of Phase 2a Amendment	May 31, 2012 National Institutes of Health Rheumatoid Arthiritis	Jun. 30, 2012 National Institutes of Health Autoimmune Disease	Jul. 31, 2011 National Institutes of Health Skin Autoimmune Inflammation	Aug. 31, 2010 National Institutes of Health HBV	Jul. 31, 2010 National Institutes of Health HPV	Sep. 30, 2008 National Institutes of Health ISS Technology
Product Information [Line Items]
Number of programs for research and early clinical development	4
Potential milestone payment							$ 260,000,000	$ 12,000,000	$ 60,000,000
Collaboration revenue	10,000,000	357,000	357,000							10,000,000	180,000	180,000			3,000,000			6,000,000	2,600,000
Revenue from milestone payment				12,000,000		3,000,000					346,000	392,000	4,500,000				20,000,000
Deferred revenue recognition period		7 years									50 months
Deferred revenue		3,900,000			4,200,000						7,200,000			7,700,000
Research collaboration and license agreement period										3 years
Cost of clinical development activities																20,000,000
Grants receivable																				400,000	600,000	600,000	1,100,000	600,000
Contract agreement period																									5 years
Contract awarded to develop technology																									$ 17,000,000